Fintel reports that on September 8, 2023, Wedbush reiterated coverage of Chipotle Mexican Grill (NYSE:CMG) with a Outperform recommendation. Analyst Price Forecast Suggests 12.83% Upside
Fintel reports that on September 8, 2023, Northland Capital Markets maintained coverage of Planet Labs PBC - (NYSE:PL) with a Outperform recommendation.
Fintel reports that on September 8, 2023, Stephens & Co. reiterated coverage of Citizens Financial Group (NYSE:CFG) with a Overweight recommendation.
Fintel reports that on September 8, 2023, Barclays maintained coverage of Johnson & Johnson (NYSE:JNJ) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 17.04% Upside
Fintel reports that on September 8, 2023, JP Morgan maintained coverage of Apple (NASDAQ:AAPL) with a Overweight recommendation. Analyst Price Forecast Suggests 15.28% Upside
Fintel reports that on September 8, 2023, Wells Fargo maintained coverage of Marathon Petroleum (NYSE:MPC) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 4.59% Upside
Fintel reports that on September 8, 2023, RBC Capital initiated coverage of Lucid Group (NASDAQ:LCID) with a Sector Perform recommendation.
Fintel reports that on September 8, 2023, Wells Fargo maintained coverage of BlackRock Capital Investment (NASDAQ:BKCC) with a Equal-Weight recommendation.
Fintel reports that on September 8, 2023, Telsey Advisory Group maintained coverage of Designer Brands Inc - (NYSE:DBI) with a Market Perform recommendation.
Fintel reports that on September 8, 2023, RBC Capital reiterated coverage of JPMorgan Chase (NYSE:JPM) with a Outperform recommendation. Analyst Price Forecast Suggests 20.19% Upside
Fintel reports that on September 8, 2023, William Blair initiated coverage of Procter & Gamble (NYSE:PG) with a Market Perform recommendation. Analyst Price Forecast Suggests 10.40% Upside
Fintel reports that on September 8, 2023, Truist Securities maintained coverage of Broadcom (NASDAQ:AVGO) with a Buy recommendation. Analyst Price Forecast Suggests 6.18% Upside
Fintel reports that on September 7, 2023, Cantor Fitzgerald reiterated coverage of Oncternal Therapeutics (NASDAQ:ONCT) with a Neutral recommendation.